News & Coverage
Cybin Announces Completion of its 51st Pre-Clinical Psychedelic Molecule Study
Cybin Inc. ( NEO:CYBN) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the completion of its 51 st pre-clinical ...
Joplin Globe
Jun 22, 2021
A New Psychedelics Stocks ETF Just Launched: Here's Why It's Important
Psychedelics stocks could be the next big thing. For investors who prefer to buy a basket of stocks, there's now a new exchange-traded fund that focuses largely on psychedelics stocks -- the ( NYSEMKT ...
The Motley Fool on MSN.com
Jun 22, 2021
B.C. health researchers harness the 'magic' of psychedelic mushrooms
After beating what doctors told her was terminal cancer, Mona Strelaeff had hoped her health complications were behind her. Instead, what followed were years of crippling depression and anxiety. At ...
cbc.ca on MSN.com
Jun 21, 2021
The Psychedelic Capital: June 2021 Conference Returns with a Deep Dive Into Psychedelic Medicine Investment
Microdose Psychedelic Insights, a cutting-edge media company focused around promoting content, financial analysis, and engaging events designed to drive the psychedelics industry into the forefront of ...
Benzinga.com
Jun 21, 2021
REPEAT - New Psychedelic Drug Formula Believed to Work to Mitigate Neurological Damage Due to Stroke, Provisional Patent Application Filed
Core One Labs Inc. (CSE: COOL), (OTC: CLABF), (Frankfurt: LD62, WKN: A2P8K3) (the “Company”) is pleased to announce that its wholly owned subsidiary Akome Biotech Ltd. (“Akome”) has commenced the ...
YAHOO!News
Jun 21, 2021
